Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1864 results
February 2016
-
Story From Our Labs
Rediscovering the power of nature’s exquisite complexity
Read how nature's medicine chest empowers our drug discovery chemists to advance biomedical research
-
Press Release
Sandoz strengthens its biosimilars portfolio with acquisition of Pfizer's biosimilar infliximab in EEA
Sandoz acquires rights to PF-06438179 (biosimilar infliximab) in the European Economic Area (EEA)* Sandoz plans to complete Phase III development program and file for registration in the EU… -
Story Discovery
Intractable tumor cells crippled
Functional genomics study reveals a potential approach for tackling glioblastoma, pancreatic cancer and other tumors.
-
Press Release
Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
Sandoz' late-stage biosimilar pipeline gains momentum with sustained investment - five of 10 planned regulatory filings achieved Sandoz believes that the totality of evidence in its submission,… -
Story Discovery
Leveraging the liver’s ability to heal scarred tissue
A reversal in thinking about the reversibility of liver damage is changing the field of hepatology.
-
Featured News
Innovation in practice: how we form partnerships in pharma
The Novartis Business Development and Licensing team is behind many of the partnerships that fuel our innovation.
-
Story From Our Labs
Opening chemistry education to the world
Novartis taps MOOC technology to share chemistry education with the world
-
Story Discovery
Neuroscientists restore cell-to-cell signaling and sociability in autism models
Team uncovers a potential therapeutic approach for patients deficient in a protein called Shank3.
-
Featured News
How digital technologies are creating a “new normal” for people living with COPD
Learn how Novartis is working with chronic obstructive pulmonary disease (COPD) patients to develop digital health technologies that help them find their “new normal.”
-
Story Discovery
Novartis and Pfizer join forces to upend oncology dogma
Industry labs find that, contrary to earlier evidence, KRAS-driven tumors are not addicted to autophagy.
January 2016
-
Press Release
Novartis Foundation commemorates World Leprosy Day with its continued efforts to go the last mile toward elimination
2016 marks 30 years of commitment by the Novartis Foundation to support people affected by leprosy and to end this ancient disease New strategy from the Novartis Foundation to accelerate… -
Press Release
Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations
Strong growth (cc) in full year sales, core operating income and core EPS[2] Net sales up 5% (cc) and core operating income up 10% (cc) Core operating income margin up 1.3 percentage points (…